These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36449947)

  • 41. Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
    Lu D; Wang C; Qu L; Yin F; Li S; Luo H; Zhang Y; Liu X; Chen X; Luo Z; Cui N; Kong L; Wang X
    J Med Chem; 2022 Oct; 65(19):12838-12859. PubMed ID: 36153841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
    Mottamal M; Zheng S; Huang TL; Wang G
    Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
    Li Y; Wang Y; Xie N; Xu M; Qian P; Zhao Y; Li S
    Eur J Med Chem; 2015 Jul; 100():270-6. PubMed ID: 26140961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Harnessing pyrimidine as a building block for histone deacetylase inhibitors.
    Badran MM; Abbas SH; Fujita M; Abdel-Aziz M
    Arch Pharm (Weinheim); 2023 Oct; 356(10):e2300208. PubMed ID: 37462396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
    Wang J; Cao Z; Wang F; Wang P; An J; Fu X; Liu T; Li Y; Li Y; Zhao Y; Lin H; He B
    Eur J Med Chem; 2021 Dec; 225():113799. PubMed ID: 34500130
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
    Liu M; Gao S; Liang T; Qiu X; Yang X; Fang H; Hou X
    J Med Chem; 2022 Sep; 65(18):12200-12218. PubMed ID: 36097406
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
    Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
    ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, Synthesis, and Structure-Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition.
    Duan JL; Wang CC; Yuan Y; Hui Z; Zhang H; Mao ND; Zhang P; Sun B; Lin J; Zhang Z; Gao Y; Xie T; Ye XY
    J Med Chem; 2024 Mar; 67(6):4950-4976. PubMed ID: 38456618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
    Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
    J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
    Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
    Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
    Mehndiratta S; Wang RS; Huang HL; Su CJ; Hsu CM; Wu YW; Pan SL; Liou JP
    Eur J Med Chem; 2017 Jul; 134():13-23. PubMed ID: 28395150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.
    Brindisi M; Cavella C; Brogi S; Nebbioso A; Senger J; Maramai S; Ciotta A; Iside C; Butini S; Lamponi S; Novellino E; Altucci L; Jung M; Campiani G; Gemma S
    Future Med Chem; 2016 Sep; 8(13):1573-87. PubMed ID: 27556815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
    Kachhadia V; Rajagopal S; Ponpandian T; Vignesh R; Anandhan K; Prabhu D; Rajendran P; Nidhyanandan S; Roy AM; Ahamed FA; Surendran N; Rajagopal S; Narayanan S; Gopalan B
    Eur J Med Chem; 2016 Jan; 108():274-286. PubMed ID: 26689485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
    Diamond JR; Pitts TM; Ungermannova D; Nasveschuk CG; Zhang G; Phillips AJ; Bagby SM; Pafford J; Yacob BW; Newton TP; Tentler JJ; Gittleman B; Hartman SJ; DeMattei JA; Winkler JD; Wendt MK; Schiemann WP; Eckhardt SG; Liu X; Piscopio AD
    Mol Cancer Ther; 2022 Mar; 21(3):397-406. PubMed ID: 34965958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.